Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
VELUSETRAG
Prokinetics in Phase II and III stages of development | Download Table
Summary of Clinical Trials for Chronic Constipation | Download Table
PDF) Velusetrag for the treatment of chronic constipation
Full article: Velusetrag for the treatment of chronic constipation
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis | Gut
Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology
Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial - ScienceDirect
Diabetic gastroparesis: current challenges and future prospects | CEG
Current developments in pharmacological therapeutics for chronic constipation - ScienceDirect
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. - Abstract - Europe PMC
PDF) Velusetrag for the treatment of chronic constipation
Velusetrag (TD-5108) | 5-HT4R Agonist | MedChemExpress
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Tryptophan Metabolism as a Pharmacological Target: Trends in Pharmacological Sciences
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K THERAVANCE BIOPHARMA, INC.
Theravance Biopharma :: SEC Filing
Theravance Biopharma :: SEC Filing
Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double‐blind, randomised, placebo‐controlled, phase 2 study - Kuo - 2021 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Velusetrag - Wikipedia
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
Velusetrag - Wikiwand
